Special Packaging Delivers Inhaled Insulin - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Special Packaging Delivers Inhaled Insulin


Pharmaceutical Technology


Injection molding and the assembly of in-house-produced and purchased parts occurs in a Class 100,000 cleanroom. The assembly process involves manual, semiautomatic, and fully automated operations. In fact, robots extract parts from the molding machines. Because most parts snap-fit together, adhesive usage is minimal. An automated laser-coding system etches alphanumeric codes on certain components to provide lot traceability. Pad printers apply logos, which not only identify the product but also help the patient position the inhaler properly for use. Quality control is stringent. Optical scanners monitor the assembly sequence, which includes a significant amount of testing to ensure the device will be functional and reliable for the duration of its recommended one-year usage.

To mitigate the risk of supply disruptions, Nektar and Pfizer wanted more than one contract manufacturer for the inhaler and selected a European counterpart for West's Tech Group. Bespak plc (Milton Keynes, UK, http://www.bespak.com/) manufactures the inhaler at a purpose-built facility in Milton Keynes, UK.

"Although they would ordinarily be considered a competitor, we partnered on this project," says Treadaway. "They have the same molding machines, the same automation, the same molds. In addition, manufacturing processes were developed to ensure interchangeability plant-to-plant," he adds. In addition, each facility follows the same standards and complies with FDA and EC regulatory requirements to ensure each inhaler is acceptable for shipment anywhere.

In addition to filling the blisters, Pfizer's Terre Haute plant performs final kitting and distribution tasks. Patient packs come in a variety of configurations, including a combination pack that includes both 1- and 3-mg doses. An Exubera "CareKit" consists of one inhaler, a replacement chamber, and two Exubera release units that are individually packaged in sealed, thermoformed trays. The latter items also are sold separately.

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 Morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here